Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Blood Cancer Clinical Trials

A listing of Blood Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (279) clinical trials

The purpose of this Study is to find out if the study drug ruxolitinib (“Study Drug” or ruxolitinib) is safe and effective compared to anagrelide hydrochloride (also known as Agrylin® or anagrelide), in people who have Essential Thrombocythemia (ET) and are resistant to or intolerant of Hydroxyurea. 

Phase

Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Cyclophosphamide and dexamethasone are very commonly used in the treatment of multiple myeloma and are often given with a third drug (e.g. thalidomide, lenalidomide or bortezomib). The combination of conventional and new drugs has provided benefits in both overall survival and progression free survival, however there are few treatments available ...

Phase

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.

The open-label, multicenter, multinational rollover study is intended to evaluate the safety of CC-486, while providing continued treatment with CC-486 for subjects who are receiving single agent CC-486 at the time of transition to the rollover study and tolerated the protocol prescribed regimen in Celgene-sponsored trials, and whom in the ...

Phase

GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

In patients with multiple relapsed aggressive lymphoma or refractory lymphoma life expectancy is short. Without potent treatment options the remaining life span can be measured in weeks to a few months. Recently, an increasing number of reports have shown that either single agent use or the incorporation of potentially more ...

Phase

UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

This is a phase II study designed to examine the bone anabolic effect of the next generation proteasome inhibitor, ixazomib, in relapsed/refractory myeloma patients. Treatment consists of Ixazomib 4 mg on days 1, 8, 15, 22 of a 28 day cycle, for a maximum of 6 cycles. Determination of relapsed/refractory ...

Phase

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma

Busulfan Test Dose: If you agree to take part in this study, you will receive a test dose of busulfan by vein over about 60 minutes. This low-level test dose of busulfan will help the doctor decide what dose of busulfan you will receive during the study. You will most ...

Phase

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

This is a study of re-induction therapy that will comprise of three blocks of multi-agent chemotherapy. CR will be evaluated following each block of therapy. All patients will be candidates for hematopoietic stem cell transplant (HSCT) once they achieve negative minimal residual disease (MRD). If patients cannot proceed to HSCT ...

Phase

Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to 1 of 6 study cohorts, based on when you join this study and on what treatments you have already received. Participants who have already received treatments called hypomethylating agents will ...

Phase

Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse

Study Drug Administration: Each study cycle is 28 days. If you are found to be eligible to take part in this study, you will receive nivolumab by vein over about 1 hour on Days 1 and 15 of each cycle. After Cycle 6, you may receive nivolumab 1 time each ...

Phase

Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma

Study Drug Administration: Each study cycle is 28 days. You will take lenalidomide by mouth on Days 1-21 of Cycle 1. After Cycle 1, your dose of lenalidomide will increase and you will take it by mouth on Days 1-21 of Cycles 2-12. You should return all empty or leftover ...

Phase